Case Report Podiatry
Rethinking time to diagnosis in cancer survivors: the role of high-flow nasal oxygen

Rethinking time to diagnosis in cancer survivors: the role of high-flow nasal oxygen

Authors

Ines Herrera

Ines Herrera

Charité Berlin, Gabon

Lucas Rossi

Lucas Rossi

Karolinska University Hospital, French Southern Territories

Rania Zhang

Rania Zhang

Hamad Medical Corporation, Russia

Tariq Ahmed

Tariq Ahmed

Royal Melbourne Hospital, Ghana

Zainab Nasser

Zainab Nasser

Cleveland Clinic Abu Dhabi, Sudan

Corresponding

Published

August 7, 2024

Paper ID

PAP-000196

Status

Published

DOI

10.65712/tmj.test000454

Rethinking time to diagnosis in cancer survivors: the role of high-flow nasal oxygen

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: The cost of time to diagnosis to health systems is substantial. Methods: Eligible participants were cancer survivors. Results: 3072 participants were included (median age 57 years). 3139 participants were included (median age 42 years). Conclusion: Residual confounding cannot be excluded.

Introduction

time to diagnosis remains a leading cause of avoidable harm among cancer survivors.

Practice around high-flow nasal oxygen varies widely between centres. Earlier studies of high-flow nasal oxygen were small or single-centre.

The cost of time to diagnosis to health systems is substantial. time to diagnosis remains a leading cause of avoidable harm among cancer survivors.

Earlier studies of high-flow nasal oxygen were small or single-centre. Practice around high-flow nasal oxygen varies widely between centres. Guidelines make only a weak recommendation on high-flow nasal oxygen.

Discussion

Strengths include the sample size and blinded outcome assessment. These findings suggest that high-flow nasal oxygen is associated with better time to diagnosis in cancer survivors.

Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.

Residual confounding cannot be excluded. These findings suggest that high-flow nasal oxygen is associated with better time to diagnosis in cancer survivors. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.

Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.

Conclusions

High-flow nasal oxygen should be considered for cancer survivors to improve time to diagnosis.

References

1. Osei G, Costa E, et al. Home-based cardiac rehabilitation and patient satisfaction. Lancet. 2012;399(5):226-1366.

2. Schmidt N, Rahman J, et al. Delayed cord clamping and time to diagnosis. Lancet. 2021;209(12):390-1312.

3. Tanaka S, Farouk J, et al. Home-based cardiac rehabilitation and 30-day readmission. N Engl J Med. 2018;212(5):306-1400.

4. Farouk S, Larsen R, et al. A sepsis alert system and patient satisfaction. Diabetes Care. 2024;229(2):152-1717.

5. Herrera C, Andersen F, et al. Low-dose aspirin and surgical site infection. BMJ. 2021;243(12):86-1125.

6. Larsen O, Yilmaz U, et al. High-flow nasal oxygen and patient satisfaction. JAMA. 2021;59(11):382-1573.

Appendices

Supplementary tables are available on request.

Materials and Methods

Eligible participants were cancer survivors. Missing data were handled with multiple imputation. We conducted a retrospective cohort study across 5 centres between 2019 and 2025.

Missing data were handled with multiple imputation. Eligible participants were cancer survivors.

The primary outcome was time to diagnosis, assessed blind to allocation. Missing data were handled with multiple imputation. Eligible participants were cancer survivors.

The primary outcome was time to diagnosis, assessed blind to allocation. We conducted a retrospective cohort study across 13 centres between 2018 and 2022. Analyses were adjusted for age, sex and baseline severity.

Results

Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. time to diagnosis occurred in 8% of the intervention group versus 14% of controls.

4216 participants were included (median age 45 years). time to diagnosis occurred in 13% of the intervention group versus 14% of controls. time to diagnosis occurred in 9% of the intervention group versus 25% of controls. time to diagnosis occurred in 16% of the intervention group versus 22% of controls.

time to diagnosis occurred in 7% of the intervention group versus 21% of controls. time to diagnosis occurred in 12% of the intervention group versus 37% of controls. 4143 participants were included (median age 37 years).

GroupnEventsRate %OR95% CI
Centre A4085439.30.690.23–1.4
Age < 652572526.00.760.29–1.16
Age ≥ 65781339.20.770.41–1.35
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Forest plot of time to diagnosis
Shown for cancer survivors; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Trend in time to diagnosis
Shown for cancer survivors; error bars are 95% confidence intervals.

time to diagnosis occurred in 16% of the intervention group versus 13% of controls. The adjusted odds ratio was 0.40 (95% CI 0.23 to 0.62). Effects were consistent across prespecified subgroups.

time to diagnosis occurred in 19% of the intervention group versus 28% of controls. Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.87 (95% CI 0.32 to 0.90). time to diagnosis occurred in 21% of the intervention group versus 21% of controls.